Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety and Efficacy of Gabapentin in Postherpetic Neuralgia

ClinicalTrials.gov ID: NCT00636636

Public ClinicalTrials.gov record NCT00636636. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Postherpetic Neuralgia

Study identification

NCT ID
NCT00636636
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Depomed
Industry
Enrollment
452 participants

Conditions and interventions

Interventions

  • Gabapentin Extended Release tablets Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 29, 2008
Primary completion
Jul 31, 2009
Completion
Aug 31, 2009
Last update posted
Feb 21, 2012

2008 – 2009

United States locations

U.S. sites
36
U.S. states
22
U.S. cities
36
Facility City State ZIP Site status
Not listed Birmingham Alabama
Not listed Tuscaloosa Alabama
Not listed Phoenix Arizona
Not listed Little Rock Arkansas
Not listed Lancaster California
Not listed Los Angeles California
Not listed Pismo Beach California
Not listed Colorado Springs Colorado
Not listed Pueblo Colorado
Not listed Daytona Beach Florida
Not listed Naples Florida
Not listed New Port Richey Florida
Not listed Orlando Florida
Not listed Tampa Florida
Not listed Marietta Georgia
Not listed Honolulu Hawaii
Not listed Elk Grove Village Illinois
Not listed Shreveport Louisiana
Not listed West Yarmouth Massachusetts
Not listed Ann Arbor Michigan
Not listed Florissant Missouri
Not listed Jefferson City Missouri
Not listed Albuquerque New Mexico
Not listed High Point North Carolina
Not listed Bismarck North Dakota
Not listed Fargo North Dakota
Not listed Canton Ohio
Not listed Cincinnati Ohio
Not listed Kettering Ohio
Not listed Warwick Rhode Island
Not listed Murrells Inlet South Carolina
Not listed Pelzer South Carolina
Not listed Tullahoma Tennessee
Not listed Austin Texas
Not listed Longview Texas
Not listed Spokane Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00636636, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 21, 2012 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00636636 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →